Study Title: “Open-label, multi-site trial for cycle control and tolerance to SH D 592 compared to MERCILON® in fertile women”].
Study End Date: October/1998
Study Title: Multi-Site, International, Open-Label, Phase III Trial of Contraceptive Efficacy and Safety of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Women of Childbearing Potential in the Americas on Bone Mineral Density [BMD] – MAIN TRIAL”].
Study End Date: 28/June/2002
Study Title: Multi-Site, International, Open-Label, Phase III Trial of the Contraceptive Efficacy and Safety of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Women of Childbearing Potential in the Americas (Including a Comparative Subtrial of the Effects of DMPA-SC and DMPA-IM) on Bone Mineral Density [BMD] – SUBTRIAL.
Study End Date: 10/Oct/2003
Study Title: Multinational, multi-site, randomized, parallel-group Phase III trial comparing depot medroxyprogesterone acetate vs. subcutaneous leuprolide acetate for reducing pain associated with endometriosis in women, including assessments of bone mineral density and subtrials of coagulation and lipid profile (not applicable to Brazil)”].
Study End Date: September/2003
Study Title: Phase III, open-label, multi-site, multinational trial to evaluate the contraceptive effect of medroxyprogesterone acetate (MPA 20 mg) and estradiol cypionate (E2C 5 mg) in injectable suspension for subcutaneous administration”].
Study End Date: 29/Apr/2003
Study Title: “Evaluation of the effects of SHT 470 FA (30 mg estradiol and 3 mg drospirenone) on general well-being and symptoms related to fluid retention in women desiring contraception”]. Open, uncontrolledstudy, lasting 6 cycles.
Study End Date: April/2004
Study Title: Open, non-comparative, prospective study to evaluate cycle control, tolerability and acceptance of a new oral contraceptive containing Gestodene 60 mcg and Ethinylestradiol 15 mcg (Minesse)”].
Study End Date: September/2003
Study Title: Phase IIIb - Double-blind, double-dummy, randomized, comparative study of the efficacy and safety of VALDECOXIB 40 mg once a day, and if necessary, an additional dose of 40 mg on the first day of the menstrual cycle; and once a day on the following days; and PIROXICAM 40 mg once a day, in the treatment of patients with primary dysmenorrhea”].
Study End Date: July/2003
Study Title: Prospective, Double-Blind, Randomized Study on the Effect of Premarin® Vaginal Cream and Low-Dose Premarin/MPA on Dyspareunia, Atrophic Vaginitis, Sexual Function, Quality of Life and Genital Blood Flow”].
Study End Date: April/2004
Study Title: Multi-Site, International, Open-Label, Phase III Trial of the Contraceptive Efficacy and Safety of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Women of Childbearing Potential in the Americas (Including a Comparative Subtrial on the Effects of DMPA-SC and DMPA-IM) on Bone Mineral Density [BMD] – Subtrial Extension, Version September 24, 2003”].
Study End Date: October/2004
Study Title: Phase III, randomized, multi-site trial to evaluate the efficacy, tolerability, and safety of the combination of Clindamycin 100mg and Ketoconazole 400mg in vaginal capsules compared to the combination of Tetracycline 100mg and Amphotericin 50mg in vaginal cream, for the treatment of bacterial vaginosis and vaginal candidiasis alone or in combination (mixed vaginitis)”].
Study End Date: September/2010
Study Title: National Clinical Trial, Phase III, open, non-comparative, prospective, to evaluate the Therapeutic Efficacy and Tolerability of the Naturetti® Capsule composition (Cassia fistula + Senna alexandrina Miller), in Chronic Functional Intestinal Constipation”].
Study End Date: October/2012
Study Title: National Clinical Trial, Phase III, open, prospective, to evaluate the Therapeutic Efficacy and Tolerability of the composition Naturetti® (Cassia fistula + Senna alexandrina Miller), in Chronic Functional Intestinal Constipation”].
Study End Date: October/2012
Study Title: Double-blind, randomized, double-dummy non-inferiority study of the efficacy of ketorolac tromethamine oral solution compared to naproxen in the treatment of patients with moderate to severe low back pain”].
Study End Date: December/2013
Study Title: Phase III, multi-site, prospective, comparative non-inferiority, single-blind and randomized clinical trial to evaluate the efficacy and tolerability of the use of Famciclovir 125 mg tablet (PENVIR®) compared to Aciclovir 200 mg tablet (ZOVIRAX®) for the treatment of patients with recurrent genital herpes caused by the HSV virus”].
Study End Date: February/2015
Study Title: International, cross-sectional, non-interventional, observational study to describe the management and control of LDL-cholesterol versus ESC/EAS guidelines of patients receiving lipid-lowering treatments in countries outside the USA and Europe under real-life conditions”].
Study End Date: August/2016
Study Title: International, cross-sectional, non-interventional, observational study to describe the management and control of LDL-cholesterol versus ESC/EAS guidelines of patients receiving lipid-lowering treatments in countries outside the USA and Europe under real-life conditions”].
Study End Date: May/2017
Study Title: Phase III clinical trial in patients diagnosed with endometriosis”]. SOLSTICE.
Study End Date: December/2016
Study Title:Phase III clinical trial in patients diagnosed with endometriosis”]. GLOW.
Study End Date: November/2016
Study Title: Phase III, prospective, multi-site, single-blind, randomized, superiority clinical trial to evaluate the efficacy and safety of the combination of methenamine 250 mg + methylthioninium chloride 20 mg compared to phenazopyridine 100 mg in the symptomatic control of dysuria.” Phase III clinical trial, in a patient with dysuria”].
Study End Date: May/2017
Study Title:Phase III, national, multi-site, randomized, double-blind, prospective, parallel clinical trial to evaluate the efficacy and safety of Orlistat 60mg as an adjuvant treatment for obesity in adults”].
Study End Date: September/2017
Study Title: Multi-Site, randomized, double-blind clinical trial of superiority of the combination of bromopride and simethicone versus bromopride alone in research participants diagnosed with functional dyspepsia”].
Study End Date: September/2018
Study Title: Clinical Trial to evaluate the efficacy and safety of the pediatric drug Naridrin® (naphazoline hydrochloride + mepyramine maleate + dexpanthenol) produced by EMS SA, compared to the drug Afrin® (oxymetazoline hydrochloride 0.05%) produced by Hypermarcas S.A. in improving nasal congestion”].
Study End Date: February/2019
Study Title: Randomized, double-blind, placebo-controlled study to evaluate the effects of bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at risk for, cardiovascular disease who are statin intolerant”].
Study Title: Phase 3 International, Randomized, Double-Blind, Placebo-Controlled Study of Withdrawal of RelugolixCoadministered with Estradiol and Norethisterone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroid”]. Liberty 1
Study End Date: May/2019
Study Title: Clinical Trial Phase 3 International, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Trial to Evaluate Relugolix Co-Administered with and Without Estradiol and Low-Dose Norethisterone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroid”] - Liberty 2
Study End Date: August/2019
Study Title: Phase III, national, multi-site, randomized, double-blind, double-masked, superiority clinical trial to compare the efficacy of the combination of Ketoprofen + Cyclobenzaprine + Caffeine in relation to Cyclobenzaprine + Caffeine (Miosan Caf®) in the treatment of musculoskeletal pain in adults”].
Study End Date: March/2020
Study Title: Phase III, national, multi-site, randomized, double-blind, double-masked, superiority clinical trial to compare the efficacy of the combination of Ketoprofen + Cyclobenzaprine + Caffeine in relation to Cyclobenzaprine (Miosan®) in the treatment of musculoskeletal pain in adults”].
Study End Date: August/2020
Study Title: LIBERTY EXTENSION Clinical Trial: International, extension, phase 3, open-label, single-group, long-term efficacy and safety trial to evaluate relugolix co-administered with estradiol and low-dose norethisterone acetate in women with heavy menstrual bleeding associated with uterine fibroids”].
Study End Date: September/2021
Study Title: “CLEAR Randomized, double-blind, placebo-controlled study to evaluate the effects of bempedoic acid (etc-1002) on the occurrence of major cardiovascular events in patients with, or at risk of, cardiovascular disease who are statin intolerant”].
Study End Date: October/2022
Study Title: SPIRIT EXTENSION Clinical Trial: International, extension, phase 3, open-label, single-group efficacy and safety study to evaluate Relugolix co-administered with estradiol and low-dose norethisterone acetate in women with pain associated with endometriosis”].
Study End Date: November/2022
Study Title: Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of estetrol in the treatment of moderate to severe vasomotor symptoms in postmenopausal women (E4Comfort I Study)”].
Study End Date: November/2022
Study Title: Phase 3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of estetrol in the treatment of moderate to severe vasomotor symptoms in postmenopausal women”].
Study Title: International, extension, phase 3, open-label, single-group, efficacy and safety study to evaluate Relugolixcoadministered with estradiol and low-dose norethisterone acetate in women with pain associated with endometriosis”]. SPIRIT 2.
Study End Date: June/2021
Study Title: A national, single-center, randomized, placebo-controlled clinical trial to investigate the benefits of the oral administration of Hydrolyzed Collagen, as a Food Supplement, in healthy women of childbearing age”].
Study End Date: July/2024
Study Title: A national, single-center, randomized, placebo-controlled clinical trial to investigate the benefits of the oral administration of Hydrolyzed Collagen, as a Food Supplement, in healthy postmenopausal women”].
Study End Date: July/2024
